Long/short equity, biotech, healthcare, small-cap

Buy Endologix: Good Long Term Bet

Endologix (NASDAQ:ELGX) has an appealing product pipeline in the field of Endovascular aortic repair, or EVAR. Its innovative products such as AFX, Nellix, and Ventana have the potential to grow its EVAR segment substantially. According to Endologix, around 63,000 abdominal aortic aneurysm, or AAA repairs were done in 2012; out of those, 75% were EVAR procedures and 25% were open surgery procedures. This depicts the dominance of EVAR in treating AAA and thus opens a significant opportunity for Endologix to excel in the field of EVAR. Further, it has an impressive historical (2008-2012) track record of driving consistent 20% plus revenue growth. Over the past three years, it has achieved a remarkable CAGR of 26%.

I expect it...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details